Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals



Availability: In stock

Special Price $ 250

BRAND : Erlonat
STRENGTH : 150mg
INGREDIENT : Anticancer-Cancer-Treatment-Natco-Erlotinib-150mg-Erlonat
COUNT : 30 Tablets

Description of Erlonat

Brand Name : Erlonat Composition : Erlotinib Manufactured by : Natco Pharma Ltd. Strength : 150 mg Dosage Form : Tablets Packing : Pack of 30 Tablets Erlonat is a anticancer drug which prevent the growth of cancer cells and reduce the spreadness in the body. Erlonat tablet indicated for non-small cell lung cancer or pancreatic cancer which spread to all over the body. It has been given after other cancer drug used without achieve success.

Pharmacology of Erlonat

PHARMACODYNAMIC: MECHANISM OF ACTION Epidermal growth factor receptor (EGFR) is demonstrated on the surface of cell of both cancer and normal cells. Erlonat plays a role in tumor cell survival and perforation by some tumour cells wave through the receptor with irrespective of EGFR mutation status. By action of Epidermal growth factor receptor, Erlonat feasibly prevent the kinase thereby inhibits autophosphorylation of tyrosine excess attached with the receptor and interferes further downstream waving. Erlonat prevention of other tyrosine kinase receptors have not been fully established. PHARMCOKINETIC: ABSORPTION: After oral administration, 60% absorbed by Erlonat and is bioavailability is subsequently increased by food (100%). Erlonat occurs peak plasma level about 4 hours after dosing. DISTRIBUTION: Erlonat bounded to plasma albumin protein and alpha-1acid glycoprotein is approximately 93%. METABOLISM: Erlonat primarily metabolized by CYP3A4 and to a lesser action by CYP1A2, and the extrahepatic isoform CYP1A1. Erlonat reach steady state plasma concentration about 7-8 days. EXCRETION: In Erlonat 150mg oral dose, 91% dose recovered, in which 83% in feces and 8% in urine and half life of 36.2 hours.

Indication of Erlonat

Erlonat is used for the first line therapy of patient who suffering from advanced non-Small cell lung cancer(NSCLC) without recover after four cycles. Erlonat is indicated for the treatment of first line therapy with metastatic pancreatic cancer.

Dose & Dosage's of Erlonat

Metastatic non-small cell lung carcinoma: Erlonat adult dose 150mg once daily in serious stage and reduce dose by slow down of 50mg when necessary. Advanced, undetectable pancreatic carcinoma: Erlonat adult dose in first line therapy with gemcitabine is 100mg. when necessary it will reduce to 50mg. CYP3A4 or CYP1A2 inhibitor patients: reduce dose in slow down of 50mg, when required. Smokers: Erlonat drug Increased dose of 50mg at 2 week interval. Erlonat should be administrated on an empty stomach(1hr before or 2 hr after meals).Erlonat is used by oral administration.

Side Effects of Erlonat

Erlonat has serious adverse reaction as follows: Kidney failure; Myocardial Infarction; Bleeding in patient taking warfarin; Cerbrovascular accident; Gastrointestinal proliferation; Hepatotoxicity with or without hepatic impairment ; interstitial lung disease; ocular discomfort; Hemolytic anemia with thrombocytopenia; Exfoliative skin disorders.

Contraindication of Erlonat

The patient with severe hypersensitivity or to any substance of Erlonat is contraindicated by drug Erlonat .

Drug Interaction of Erlonat

Reduce exposure of Erlonat tablet by interacting with potent CYP3A4 inhibitor and CYP3A4 inducers. Interaction with increased serum level of potent CYP1A2 inhibitors and CYP1A2 inducers causes altered elimination of Erlonat. Interaction with antacids and H2 receptors (increased PH) may affects the solubility of Erlonat and reduce bioavailability.

Precaution of Erlonat

If the patient has hepatic disease, lung or breathing difficulty (other than lung cancer), Erlonat should not be given without taking advice from doctors .Do not take , or products involving , unless recommended by the doctor. Patient must take Erlonat at equal time gap, if antacids are also being taken or any of its constituents, then intake is not adjustable. If the patient is pregnant or breast feeding the child then Erlonat drug should be avoided. Doctor consultation suggested for use of controlof birth during threapy with Erlonat. Whether Erlonat passes into breast milk or not is not yet established.

Usage & Safety profile of Erlonat Pregnancy & Lactation

Based on aftereffects there is positive evidence of human fetal risk In pregnant women use of Erlonat may be gain acceptable against the risk means if the drug is used in a life-threatening situation are ineffective.

Storage of Erlonat

Erlonat should be store at 250C. Do not keep medicine near to the children accessible. Erlonat store at cool and dry place and store it in its own original container after usage of medicine. Keep away from spouse or other family members avoid accidently